Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

EPA sucks booty and won’t solve.

AdvaMed 23 (AdvaMed, or the Advanced Medical Technology Association, is an American medical device trade association, based in Washington, D.C, 6/27/2023, accessed 7/19/2023, Advanced Medical Technology Association, “Docket ID No. EPA–HQ–OPP–2013–0244; U.S. Environmental Protection Agency Proposed Interim Registration Review Decision Applicable to Ethylene Oxide.” https://www.advamed.org/wp-content/uploads/2023/06/AdvaMed-Federal-Insecticide-Fungicide-Rodenticide-Act-FIFRA-Comments-062723.pdf)SAADK

EPA failed to undertake the required assessment of the “economic, social, and environmental costs and benefits of the use of” EtO.

Despite the requirement to consider economic, social, and environmental cost and benefits, the PID states: “As is typical of the Registration Review process under FIFRA, OPP did not conduct a cost analysis for the proposed mitigation in this PID.”15 Thus, EPA has not yet performed an appropriate analysis of economic, social, and environmental costs and benefits. As discussed below in Sections IV and V, the PID’s proposals would have drastic consequences for the supply chain of critical medical devices—resulting in economic, social, and public health costs—and would be extremely expensive or infeasible to implement. As explained in the Supply Chain and Capacity Considerations report by economists at the National Economics Research Associates (or NERA), the inelasticity of demand for medical devices “means that even modest sized shifts or disruptions in supply will cause medical device shortages that will affect patients.”16

These factors fall into economic, social, and public health costs and benefits that EPA is to consider as part of the “unreasonable adverse effects” standard, meaning EPA must consider them, as is consistent with EPA’s own solicitation of information on costs.

Additionally, under FIFRA, EPA must also “take into account the difference in concept and usage between various classes of pesticides” when promulgating regulations.17 Although the registration process is not a rulemaking, this statutory provision nevertheless demonstrates Congress’s special consideration that the usage and concept of different pesticides be taken into account. This further underscores the need for EPA to fully consider costs and downstream impacts to society resulting from the proposed changes to EtO labelling and use.

EPA drastically overstates the risk of EtO exposure by relying on a unit risk factor derived from flawed modeling and inconsistent with the scientific literature.

EPA’s risk assessment is fatally flawed because it is based on an IRIS risk value that is scientifically unsound.

The PID states that the “concentration at which the cancer risk is . . . not considered by OPP to be of concern” is “0.00011 ppb (0.11 ppt).”18 But EPA’s own ambient air measurements show EtO concentrations as high as 0.22 ppb or 220 ppt—two thousand times higher than the level EPA purports to use as its risk threshold.19 EtO in much higher concentrations is produced by lawnmowers (up to 18,000 ppbv) and backyard barbecue grills (5,000 ppbv).20

Exposure from natural human biological processes is even higher, up to 27,000 times EPA’s risk threshold. A recent study examined eight EtO-emitting facilities and found that average “concentrations were not substantially elevated above the related background mean concentrations” and exposure from the facilities “composed a small fraction of the endogenous” exposure.21 The 2016 EtO IRIS value creates “a serious gap in confidence in interpreting the health significance of general population E[t]O exposure,” in large part because it is not “consistent with clinical metrics for which the risk of disease does not increase significantly until the values are above the healthy population normal range defined by individual variability within the population.”22

EPA’s risk assessment arrives at an unjustifiably low IRIS value by adopting a flawed model and statistically significant over-predictions that are unsupported by epidemiological, toxicological and biological studies. Based on EPA’s risk assessment, “the background levels of [EtO] in the population would be predicted to cause more lymphoid cancer than is actually observed in the general population (and ignoring any other potential cause of lymphoid cancer).”23 In short, EPA’s risk assessment is, on its face, indefensible and scientifically unsound. Our view is shared by regulatory agencies, industry experts, and the scientific community.

Sign in to recut, update, or save this card.